Trial NCT05375760

View at ClinicalTrials.gov 
Org. Study IDs: D8850C00010
Secondary IDs: 2022-001014-20

Last trial update was posted on 2023-11-07

MeSH Interventions

Cilgavimab and tixagevimab drug combination

MeSH Conditions

COVID-19

Other Conditions

Coronavirus Disease 2019 (COVID-19)

Stopping Reasons

Sponsor terminated after review of FDA's request to halt further dosing (30Mar2023) given that AZD7442 is not active against >99% of the currently circulating SARS-CoV-2 variants in the USA, the benefit risk assessment may not be favorable

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID